Bj. Averbook et al., Coinfusion of irradiated splenocytes with low titer tumor-infiltrating lymphocytes augments antitumor efficacy in adoptive immunotherapy, J IMMUNOTH, 22(2), 1999, pp. 124-134
We hypothesized that adoptively increasing the density of antigen-presentin
g cells (APCs) at a tumor site would improve tumor-infiltrating lymphocyte
(TIL) in vivo antitumor efficacy. Irradiated splenocytes were used as crude
APCs. Alone, they did nor have in vitro antitumor activity nor did they au
gment TIL efficacy in vitro. Pulmonary metastases were established by intra
venous (IV) injection of 5 x 10(5) MC-38 tumor into irradiated C57Bl/6 mice
(500 cGy). After 3 days, MC-38 TIL (0.1, 0.5, and 1 x 10(6) cells) +/- irr
adiated splenocytes (5,000 cGy) as APCs were administered intravenously (0.
25, 0.5, and I x 10(6) cells) to each group (n = 5/group). Interleukin-2 (6
0,000 TU) was injected intraperitoneally three times daily for 3 days. Mice
were sacrificed 9 days later and metastases elaborated in blinded fashion.
A titer of 1 x 106 TIL, completely eradicated pulmonary metastases. In two
consecutive experiments, when increasing titers of irradiated splenocytes
were coinfused with a constant titer of TIL that did not completely eradica
te pulmonary metastases, a moderate reduction in pulmonary metastases was o
bserved. The contribution of splenocytes to an improvement in TTL antitumor
efficacy was not altered when irradiated splenocytes derived from mice bea
ring 10-day subcutaneous MC-38 tumors were used. The coinfusion of nonirrad
iated splenocytes did not Improve TIL antitumor in vivo activity. Activated
B cells (expressing ICAM-1, B7.1 and B7.2) had no effect on in vitro tumor
lysis and did not augment in vivo TIL efficacy. The results show a modest
but statistically significant improvement in adoptive immunotherapy antitum
or efficacy with fewer TIL by coinfusion of irradiated splenocytes. Further
studies to characterize the active potential APC cell subpopulation and to
clarify the mechanism(s) responsible for in vivo augmentation of TIL antit
umor efficacy an in progress.